echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Once troubled RNAi technology will eventually make a comeback

    Once troubled RNAi technology will eventually make a comeback

    • Last Update: 2022-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Text: Zhang Hu

    Recently, transactions in the RNAi field have been active


    On November 18, Novo Nordisk announced the acquisition of Dicerna for US$3.


    As multinational pharmaceutical companies continue to deploy RNAi head companies, this once troubled technology will eventually make a comeback


    RNAi mechanism

    RNAi mechanism

    RNA interference (RNAi) is a biological process in which RNA molecules participate in the sequence-specific inhibition of gene expression by double-stranded RNA through translational or transcriptional inhibition


    Two types of small ribonucleic acid (RNA) molecules—microRNA (miRNA) and small interfering RNA (siRNA)—are at the heart of RNA interference


    The RNAi pathway exists in many eukaryotes, including animals, and is initiated by the enzyme Dicer, which cleaves long double-stranded RNA (dsRNA) molecules into short double-stranded fragments of approximately 21 nucleotides of siRNA


    Figure 2.


    RNAi and the Nobel Prize: There are successes and regrets

    RNAi and the Nobel Prize: There are successes and regrets

    On October 2, 2006, Stanford University professor Andrew Z.


    2006 Nobel Prize in Medicine and Physiology

    Subsequently, three scientists including the School of Biotechnology of the University of Cambridge in the United Kingdom expressed to the famous British magazine "Nature" that they regretted that scientists in the field of plant RNAi research were not included in the Nobel Prize for RNAi, and believed that this was a "grave" error" (serious error)


    Industry leader:

    Industry leader:

    Alnylam Pharmaceuticals

    Alnylam Pharmaceuticals

    Currently, 4 RNAi drugs have been approved by FDA or EMA, namely: Onpattro (patisiran), Givlaari (givosiran), Lumasiran (Oxlumo) and Inclisiran (Leqvio)


    Without exception, the above four drugs that have been approved for marketing are all developed by Alnylam and its partner companies


    Founded in 2002, Alnylam focuses on four areas: genetic diseases, liver infectious diseases, cardiometabolic diseases and central nervous system/ophthalmic diseases


    Alnylam conjugated siRNA to N-Acetylgalactosamine (GalNAc) to form GalNAc-siRNA conjugates, in which GalNAc ligands can bind to the Asialoglycoprotein receptor (ASGPR) expressed by hepatocytes and targeted delivery of siRNA to hepatocytes


    In order to improve the efficiency of gene silencing, Alnylam also used enhanced stabilization chemistry (ESC) technology to make some modifications to the RNA strand, and developed the ESC+ GalNAc-siRNA platform technology accordingly


    Alnylam R&D pipeline

    Another giant, Dicerna:

    Another giant, Dicerna:

    Extensive cooperation with MNC

    Extensive cooperation with MNC

    Founded in 2006, Dicerna is a Cambridge, Massachusetts-based company dedicated to the use of RNAi to treat disease


    Dicerna's proprietary RNAi technology platform, called GalXCTM, silences disease genes in the liver


    In 2018, Dicerna partnered with Alexion to co-develop subcutaneously delivered GalXC RNAi molecules targeting two complement pathway targets for the treatment of complement-mediated diseases
    .

    Dicerna is also working closely with Eli Lilly to develop new medicines in cardiometabolic disease, neurodegeneration and pain using the GalXCTMRNAi technology platform
    .

    summary

    summary

    In China, leading companies in the field of RNAi include Sirnaomics, Ribo Bio, and Genkey Gene
    .
    Sirona Pharma utilizes pluripotent siRNA cocktail design and nanoparticle-enhanced therapeutic delivery to treat diseases, including anti-fibrosis and cancer therapy
    .
    Genkey Gene is mainly an RNAi service provider, providing RNAi product production and R&D services
    .

    Domestic RNAi therapy is still in its infancy.
    In addition to STP705, a dual-target inhibitor based on small interfering nucleic acid from Sirona Pharmaceuticals, which is undergoing clinical trials in various diseases including cholangiocarcinoma, hepatocellular carcinoma and primary sclerosing cholangitis, The rest are still in the blank stage
    .

    RNAi technology specifically targets mRNA and modulates protein expression, and has great potential for silencing disease-related genes
    .
    Although the current RNAi therapy still faces many challenges in the process of clinical translation, we have reason to believe that with the continuous iteration of delivery vehicles or binding vehicles, the development of safe, precise and efficient delivery platforms will play an important role in promoting RNAi therapy.

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.